In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp Growth Tied To Market Penetration, Not Share Gains, Amgen Says

Executive Summary

Amgen expects future Aranesp growth to come from greater market penetration rather than market share gains as a result of the shift to average sales price-based reimbursement under Medicare Part B

You may also be interested in...



Amgen Sizes Up Strategy: Small-Scale Acquisitions, Large-Scale R&D

Amgen's growth strategy calls for heavy investment in research & development and targeted agreements to expand its pipeline, rather than large-scale acquisitions, CEO Kevin Sharer said

Amgen Sizes Up Strategy: Small-Scale Acquisitions, Large-Scale R&D

Amgen's growth strategy calls for heavy investment in research & development and targeted agreements to expand its pipeline, rather than large-scale acquisitions, CEO Kevin Sharer said

Amgen To Study Aranesp Anemia Indication In Heart Failure Patients

Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure

Related Content

UsernamePublicRestriction

Register

PS044952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel